

## eCTD Updates

### **Jonathan Resnick**

Project Management Officer
Office of Business Informatics
CDER | US FDA

SBIA REdl Event– June 6, 2022



## **Learning Objectives**



- Describe updates to eCTD validations
- Locate latest version of eCTD guidance, specifications, and validations
- Review eCTD submission metrics
- List the 5 most common errors made when submitting in eCTD format
- Review most common questions eSub team receives
- Prepare for the next major version of eCTD



## eCTD validations: What's new?



### Module 1 using DTD 2.01 no longer supported

- Older version of eCTD M1, utilizing DTD 2.01, no longer supported
- DTD 3.3 required to pass validation
- For more information, please see Federal Register Notice located here:
   <a href="https://www.regulations.gov/document?D=FDA-2018-D-1216-0017">https://www.regulations.gov/document?D=FDA-2018-D-1216-0017</a>



## eCTD validations: What's new?




#### eCTD validations 1306 and 1323 elevated to high severity errors

- FDA rejecting submissions which fail eCTD validations 1306 and 1323
- 1306: "No leaf element for file"
- 1323: "No file for leaf element"
- For more information, please see Federal Register Notice located here:
   <a href="https://www.regulations.gov/document?D=FDA-2018-D-1216-0019">https://www.regulations.gov/document?D=FDA-2018-D-1216-0019</a>




### Impacts from 1306 Errors






### Impacts from 1323 Errors



Files appear to be in the submission but can't be located by reviewers or FDA systems







# Locate latest version of eCTD guidance, specifications, and validations



### www.fda.gov/ectd

- Latest Guidance
- eCTD Submission Standards
  - eCTD specifications
  - eCTD validations
- Important Dates, Notices, Past Presentations, and More

### **Electronic Common Technical Document (eCTD)**



The eCTD is the standard format for submitting applications, amendments, supplements, and reports to FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). Please refer to the <a href="https://example.com/ectal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-actal-acta

#### **Important Dates**

Per the FDA Data Standards Catalog, the electronic submission of standardized SEND datasets to CBER is required for NDA, BLA, ANDA, and Commercial IND. FDA plans to apply eCTD validation 1734, 1735, 1736, and 1737 when CBER submissions contain content under module 4 beginning March 16, 2023. Please see the Federal Register:: Electronic Submissions; Data Standards; Support for Standard for the Exchange of Nonclinical Data, the Study Data Technical Conformance Guide, and the eCTD Validation Criteria (error code 1734, 1735, 1736, 1737) for details

#### **Ouick Links**

- NDA to BLA eCTD Transition
   Instruction to Industry (PDF 90
   KB)
- eCTD Guidance (Final, Rev 7) (PDF -11 KB)
- eCTD Submission Standards (y4.4) (PDF - 130 KB) NEW
- FDA Data Standards Catalog
- eCTD Technical Conformance Guide (PDF - 303 KB)
- Drug Master Files (DMFs)
- eCTD 4.0

#### Notices

 FDA FR Notice on high severity eCTD validations 1306 &1323




## eCTD Submission Metrics



### CDER Submissions October 1, 2021 through April 30, 2022

**Percent of Submissions by Electronic Format** 

203,000 Total Submissions




ECTD	94%
NON ECTD	5%
PAPER	1%



## Top 5 eCTD Rejection Reasons








## Top 5 eCTD Rejection Reasons





### Most common High Error Codes

- Code 2034 Submission Type invalid for Application Type
- Code 2022 Submission Sub-Type is invalid for Submission Type
- Code 1734 A dataset named ts.xpt with information on study start date must be present for each study in Module 4, sections 4.2.3.1, 4.2.3.2, 4.2.3.4, and in Module 5, sections 5.3.1.1, 5.3.1.2, 5.3.3.1, 5.3.3.2, 5.3.3.3, 5.3.3.4, 5.3.4, 5.3.5.1, 5.3.5.2
- Code 1789 A file has been submitted in a study section without providing an STF file. STFs are not required for 4.3 Literature references, 5.2 Tabular listings, 5.4 Literature references and 5.3.6 Postmarketing reports

## Challenge Question #1



## Most eCTD submission failures are due to:

- A. Duplicate sequence number
- B. eCTD validation error
- C. Submission sent to wrong Center
- D. Mismatch between data included in eCTD message and application form





- Where do I place content?
- How do I send ECG waveforms?
- What eCTD Submission Type/Sub-Type should be used?
- How to remove duplicate content?
- What file formats are expected?





### Where do I place content?

#### **Resources:**

- ✓ The Comprehensive
   Table of Contents
   Headings and Hierarchy
- ✓ M4 Organization of the Common Technical <u>Document for the Registration of</u> <u>Pharmaceuticals for Human Use Guidance for Industry</u>
- ✓ FDA Regulatory Project Manager
- ✓ esub@fda.hhs.gov

The Comprehensive Table of Contents Headings and Hierarchy

#### Module 1 Administrative information

1.1 Forms

Form [form-type]

1.2 Cover letters

1.3 Administrative information

1.3.1 Contact/sponsor/applicant information

1.3.1.1 Change of address or corporate name

1.3.1.2 Change in contact/agent

1.3.1.3 Change in sponsor

1.3.1.4 Transfer of obligation

1.3.1.5 Change in ownership of an application or reissuance of license

1.3.2 Field copy certification

1.3.3 Debarment certification

1.3.4 Financial certification and disclosure

1.3.5 Patent and exclusivity

1.3.5.1 Patent information

1.3.5.2 Patent certification

1.3.5.3 Exclusivity claim

1.3.6 Tropical disease priority review voucher

#### 1.4 References

1.4.1 Letter of authorization

1.4.2 Statement of right of reference

1.4.3 List of authorized persons to incorporate by reference





### How do I send ECG waveforms?

### Resources:

✓ eCTD Technical Conformance Guide

✓ Interdisciplinary Review Team for Cardiac Safety Studies (formerly QT-IRT)





### What eCTD Submission Type/Sub-Type should be used?

#### Resources:

✓ <u>The eCTD Backbone Files</u>

<u>Specification for Module 1</u>

## The eCTD Backbone Files Specification for Module 1 Table 2: Submission Types and Descriptions of Use

Submission Type	Submission Sub-Type	Supplement Effective Date Type (if applicable and submission-sub-type = "application")	Valid For Application Types
Original Application	Presubmission Application Amendment Resubmission		IND, NDA, ANDA, BLA, DMF, EUA
Efficacy Supplement	Presubmission		NDA, BLA
	Application	Prior Approval Supplement (PAS)	1
	Amendment Resubmission		
Chemistry Manufacturing	Presubmission		NDA, ANDA, BLA
Controls Supplement	Application	Prior Approval Supplement (PAS), Changes Being Effected (CBE-0), or Changes Being Effected 30 (CBE-30)	
	Amendment Resubmission		
Labeling Supplement	Presubmission		NDA, ANDA, BLA
	Application	Prior Approval Supplement (PAS) or Changes Being Effected (CBE-0)	
	Amendment Resubmission		
REMS Supplement	Application	Prior Approval Supplement (PAS) or Changes Being Effected (CBE-30)	NDA, ANDA, BLA
	Amendment Resubmission		
Annual Penort	Peport		IND NDA ANDA





## How to remove duplicate content?

- ✓ Remove document: Use "delete" eCTD lifecycle operator in next eCTD sequence
- ✓ Remove duplicate heading (e.g., Multiple "3.2.P"): Remove all documents under the duplicate heading(s) and rereference under the heading that should remain





### What file formats are expected?

#### **Resources:**

✓ <u>Specifications for File Format</u>
<u>Types</u>

## Specifications for File Format Types Using eCTD Specifications

File Type	File Format	Format Name	Accepted location in eCTD	Archive Format Copy	Permissible Uses
Documents					
	.pdf	Portable Document Format	M1 – M5		
		Microsoft	M1.14, 1.16		
	.doc	Word document	M2.3, M2.7	PDF	ANDA
	.doex	Microsoft Word Open M1.14, 1.16			
		XML document	M2.3, M2.7	PDF	ANDA
	.txt	Text file	M3 - M5		
	.xls	Microsoft Excel document	M3 – M5	PDF	
	.xlsx	Microsoft Excel Open XML document	M3 – M5	PDF	
Images					
	hmn	Bitmap	M1 15		



## Challenge Question #2



# Where can I locate valid eCTD Submission Type/Sub-Type combinations?

- A. Specifications for File Format Types
- B. eCTD Comprehensive Table of Contents Headings and Hierarchy
- C. The eCTD Backbone Files Specification for Module 1
- D. Interdisciplinary Review Team for Cardiac Safety Studies (formerly QT-IRT)



## The Road Ahead



### Next Major Version of eCTD is eCTD v4

- Regulatory Authorities started implementations
- ICH eCTD v4 Implementation Package is Published
- FDA Regional eCTD v4 Implementation Package, Technical Conformance Guide, and Validation Specifications are Published
- FDA Timeline to accept eCTD v4 currently planned for late 2023
- Please see <u>FDA's eCTD v4 implementation page</u> for more details



### Resources



- Web page for latest version of eCTD guidance, specifications, and validations
- eCTD Comprehensive Table of Contents Headings and Hierarchy
- M4 Organization of the Common Technical Document for the Registration of Pharmaceuticals for Human Use Guidance for Industry
- eCTD Technical Conformance Guide
- Interdisciplinary Review Team for Cardiac Safety Studies (formerly QT-IRT)
- The eCTD Backbone Files Specification for Module 1
- Specifications for File Format Types
- FDA's eCTD v4 implementation page



## Summary



- Module 1 DTD v3.3 required to pass validation
- Check FDA's eCTD webpage, <u>www.fda.gov/ectd</u> for announcements and updates
- Most common eCTD submission mistake is using a duplicate sequence number
- FDA is testing the next major version of eCTD (version 4)





## Questions?

Please join us for a live Q&A panel after this presentation

Have questions after the conference? Please send to <a href="mailto:esub@fda.hhs.gov">esub@fda.hhs.gov</a>



